Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress

Michael D. Nyquist, Alexandra Corella, Ilsa Coleman, Navonil De Sarkar, Arja Kaipainen, Gavin Ha, Roman Gulati, Lisa Ang, Payel Chatterjee, Jared Lucas, Colin Pritchard, Gail Risbridger, John Isaacs, Bruce Montgomery, Colm Morrissey, Eva Corey, Peter S. Nelson

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

Nyquist et al. demonstrate that TP53 and RB1 loss in prostate carcinoma (PC) attenuates AR signaling and enhances cell proliferation but does not uniformly induce neuroendocrine phenotypes. PCs with TP53/RB1 loss resist a wide range of cancer therapeutics but respond to PARP and ATR inhibition, likely reflecting enhanced replication stress.

Original languageEnglish (US)
Article number107669
JournalCell Reports
Volume31
Issue number8
DOIs
StatePublished - May 26 2020

Keywords

  • ATR
  • DNA damage
  • PARP
  • RB1
  • TP53
  • androgen receptor
  • antiandrogen
  • neuroendocrine
  • plasticity
  • prostate cancer

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology

Fingerprint

Dive into the research topics of 'Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress'. Together they form a unique fingerprint.

Cite this